LaNova Medicines Limited
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS13
PHASE 3 / 2-31
RECRUITING9
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO50%
Delay Index: of 8 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.8 months). See all sponsors →
Open LaNova Medicines Limited on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| LM-24C5 NCT06187402 |
P1/2 | Recruiting | Advanced Solid Tumor | 49 | 2026-06-30 (+13 mo) |
| LM-108 NCT05518045 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 392 | 2026-10-31 (+15 mo) |
| LM-299 NCT06650566 |
P1/2 | Recruiting | Malignant Tumors | 108 | 2026-12 |
| LM101 NCT05615974 |
P1/2 | Recruiting | Malignant Tumors | 139 | 2027-01-11 (+25 mo) |
| LM-168 NCT06868199 |
P1/2 | Recruiting | Advanced Solid Tumours | 87 | 2027-08-01 |
| LM-168 NCT07669415 |
P2 | Recruiting | Advanced Solid Tumor | 108 | 2027-12-15 |
| LM-108 NCT06873854 |
P2 | Not yet recruiting | Advanced Solid Tumor | 84 | 2028-01-26 |
| LM-24C5 NCT07387081 |
P2 | Recruiting | Advanced Solid Tumor Cancer | 130 | 2028-05-21 |
| LM-350 for injection NCT07112222 |
P1/2 | Recruiting | Malignant Tumors | 80 | 2028-06-30 |
| LM-108 in combination with Toripalimab NCT07362186 |
P3 | Recruiting | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | 400 | 2028-08-17 |
| LM-2417 NCT06682780 |
P1/2 | Recruiting | Advanced Solid Tumor | 320 | 2028-12-25 (+13 mo) |
| LM-364 for injection NCT07694765 |
P1/2 | Not yet recruiting | Malignant Tumors | 90 | 2028-12-31 |
| LM364 NCT07847905 |
P1/2 | Enrolling by invitation | Advanced Solid Tumor Cancer | 90 | 2030-10-19 |